Tralokinumab Demonstrates Sustained Real-World Effectiveness in Patients With Skin of Color and Atopic Dermatitis
Final data from the international TRACE study demonstrate that tralokinumab provides sustained real-world improvements in disease severity and quality of life in patients with atopic dermatitis (AD) and skin of color (SoC), a population often underrepresented in clinical research.
“The clinical presentation of AD varies across different skin tones, posing unique challenges for diagnosis and management,” the investigators noted, highlighting the importance of evaluating treatment outcomes in this group. “People with SoC may have higher AD prevalence and severity but remain underrepresented in dermatologic research.”
TRACE is a prospective, non-interventional study evaluating tralokinumab in routine clinical practice. Of 824 patients in the full analysis set, 131 (15.9%) had SoC (Fitzpatrick IV–VI). Baseline disease burden was substantial, with mean Eczema and Severity Index scores of approximately 20 and mean Dermatology Life Quality Index (DLQI) scores of 13.5, indicating moderate-to-severe disease and significant quality-of-life impairment.
Clinical outcomes improved steadily over time. The proportion of patients with SoC achieving clear or almost clear skin (Investigator Global Assessment 0/1) increased from 12% at baseline to approximately 60.7% by month 12. Improvements were consistent with those observed in the overall study population.
Patient-reported outcomes also improved significantly. Mean peak pruritus scores decreased from 6.8 at baseline to approximately 3.0 at month 12, while DLQI scores improved from 13.5 to 5.6, reflecting meaningful reductions in disease burden and improved daily functioning.
“Patients with SoC experienced substantially reduced AD severity and improved QoL over 12 months of tralokinumab treatment in a real-world setting,” the authors concluded. “Improvements were comparable to those in the overall TRACE study population.”
These findings support tralokinumab as an effective treatment option across diverse patient populations and underscore the importance of real-world data in addressing gaps in dermatologic care for patients with skin of color.
Reference
Armstrong AW, Rubin C, Jarell A, et al. Real-world effectiveness of 12 months tralokinumab treatment in patients with skin of color and moderate-to-severe atopic dermatitis: final data from the prospective, non-interventional, international TRACE study. Presented at: American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, Colorado.
